Schering OTC Claritin Launch May Await Loratadine Patent Dispute Resolution
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough could be considering delaying the OTC launch of Claritin pending resolution of its underlying patent litigation for the drug
You may also be interested in...
Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval
Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy
Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval
Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy
Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval
Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy